Fred Aslan
Company: Artiva Biotherapeutics, Inc
Job title: President & Chief Executive Officer
Bio:
Fred Aslan, M.D. brings two decades of leadership in the life sciences industry as an executive, investor, and entrepreneur. Most recently, he served as President and Chief Business Officer at Vividion Therapeutics, where he led Series B financing and a $135 million collaboration with Roche. Previously, he spent 12 years with Venrock, co-founding Receptos and investing in Zeltiq and Fate Therapeutics. He also served as CEO of Adavium Medical in Brazil, scaling the company to 350 employees and over $40 million in revenue. Dr. Aslan holds degrees from Duke, Yale, and Harvard.
Seminars:
Could Artiva’s NK cells drive cell therapy-like activity with biologics-like ease of use? 10:00 am
Highlight the rationale and potential advantages of utilizing a non-genetically modified NK cell therapy in combination with monoclonal antibodies in autoimmune diseases Explore clinical data demonstrating that NK cell therapies can drive deep B-cell depletion in autoimmune disease while avoiding side effects inherent in CAR-T and TCE therapies Highlight a framework for selecting indications for different cell therapies based on…Read more
day: Conference Day 1 P1
Chair’s Opening Remarks 8:30 am
day: Conference Day 1 P1
Industry Leaders Fireside Chat: What’s Happened in the Last Year & Where is the Field Headed Next? 8:40 am
Examining the evolution of the autoimmune cell therapy field over the last year Discussing progress across autologous, allogeneic, NK and in vivo modalities to uncover development strategies Considering indication selection strategies and the potential for indication diversification beyond lupus Exploring the future of the field to effectively scale and commercialise safe, durable therapiesRead more
day: Conference Day 1 P1
Chair’s Opening Remarks 8:55 am
day: Conference Day Two P1
Panel Discussion: Discussing the Latest on the Need for Lymphodepletion in Cell Therapies to Improve Patient Access & Limit Therapeutic Side Effects 9:00 am
Identify why lymphodepletion has been used in autoimmune cell therapies Examine the impact of lymphodepletion on patient recruitment and accessibility Consider the advantages and opportunities to remove preconditioning from therapiesRead more
day: Conference Day Two P1